Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phreesia, Inc.PHR · Entity 2606 | President, Network Solutions | September 01, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phreesia, Inc.
Report date September 01, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2031-09-01 | Direct | 155,000 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 155,000 · Balance 155,000 F1: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. F2: The award was granted at a target level of 155,000 PSUs. The number of PSUs that may be earned depends on achievement of specified stock-price hurdles during the performance period beginning September 1, 2026 and ending September 1, 2031. Achievement is measured using the average closing price of the Issuer's common stock over any consecutive 60-trading-day period. Potential payouts are 0%, 50%, 100%, 150% or 200% of the target number of PSUs, subject to the award's interpolation provisions. The applicable hurdles are $17.00, $22.00, $27.00 and $32.00 per share. F3: PSUs earned with respect to an achieved hurdle vest one-third upon certification of achievement, one-third on the first anniversary of certification and one-third on the second anniversary, generally subject to continued service. Any outstanding earned PSUs vest no later than September 1, 2031. Earned and vested PSUs are settled in shares following vesting, subject to the deferred settlement provisions of the award. The actual number earned may range from zero to 200% of the target award. PSUs that are not earned by the end of the performance period are forfeited. Dividend equivalents accrue on the PSUs and are subject to the same earning and vesting conditions. Vested dividend equivalents are settled in shares when the related PSUs are settled. |
Filing footnotes · ownership attribution and instrument terms
F1: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: The award was granted at a target level of 155,000 PSUs. The number of PSUs that may be earned depends on achievement of specified stock-price hurdles during the performance period beginning September 1, 2026 and ending September 1, 2031. Achievement is measured using the average closing price of the Issuer's common stock over any consecutive 60-trading-day period. Potential payouts are 0%, 50%, 100%, 150% or 200% of the target number of PSUs, subject to the award's interpolation provisions. The applicable hurdles are $17.00, $22.00, $27.00 and $32.00 per share.
F3: PSUs earned with respect to an achieved hurdle vest one-third upon certification of achievement, one-third on the first anniversary of certification and one-third on the second anniversary, generally subject to continued service. Any outstanding earned PSUs vest no later than September 1, 2031. Earned and vested PSUs are settled in shares following vesting, subject to the deferred settlement provisions of the award. The actual number earned may range from zero to 200% of the target award. PSUs that are not earned by the end of the performance period are forfeited. Dividend equivalents accrue on the PSUs and are subject to the same earning and vesting conditions. Vested dividend equivalents are settled in shares when the related PSUs are settled.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 29, 2025 Filed Jan 31, 2025 21:23 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 500 | $29.68 | $14,841.00 |
DisclosureSEC source: 0001127602-25-002618 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,771 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 18, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.595 to $29.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:47 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,527 | $28.15 | $99,286.81 |
DisclosureSEC source: 0001127602-25-002282 · form4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,271 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of performance-based restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.75 to $28.39 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:47 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 8,158 | $27.18 | $221,773.60 |
DisclosureSEC source: 0001127602-25-002282 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,798 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of performance-based restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.75 to $27.74 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2025 Filed Jan 25, 2025 00:51 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 19,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-001983 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,956 F1 · shares: These shares represent common stock awarded due to the vesting of performance-based restricted stock units ("PSUs") for which the performance period ended on January 14, 2025. On January 23, 2025, the Compensation Committee determined and certified the number of shares of common stock earned by the Reporting Person based upon the Issuer's achievement of pre-established performance criteria. The PSUs were awarded under the Issuer's 2019 Stock Option and Incentive Plan. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:59 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 13,873 | $27.31 | $378,881.34 |
DisclosureSEC source: 0001127602-25-001745 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,392 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.025 to $27.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 23:03 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 1,946 | $26.98 | $52,505.61 |
DisclosureSEC source: 0001127602-25-001468 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,265 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.6905 to $27.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 22:21 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,133 | $26.61 | $83,355.03 |
DisclosureSEC source: 0001127602-25-001026 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,211 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 01:06 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 53,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000862 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,344 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 10% of the RSUs shall vest on January 2, 2026, 20% of the RSUs shall vest on January 2, 2027, 30% of the RSUs shall vest on January 2, 2028 and 40% of the RSUs shall vest on January 2, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 22:59 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 24 | $25.38 | $609.02 |
DisclosureSEC source: 0001127602-24-029816 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,851 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.86 to $25.58 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 01:30 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2 | $25.77 | $51.53 |
DisclosureSEC source: 0001127602-24-029756 · form4.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,875 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.665 to $25.915 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 01:30 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 59 | $25.04 | $1,477.27 |
DisclosureSEC source: 0001127602-24-029756 · form4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,877 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.60 to $25.55 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2024 Filed Dec 19, 2024 01:30 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 35 | $24.88 | $870.89 |
DisclosureSEC source: 0001127602-24-029756 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,936 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.415 to $25.18 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:13 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 11,853 | $24.85 | $294,558.90 |
DisclosureSEC source: 0001127602-24-029339 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,354 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 18, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $25.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 21:51 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 1,100 | $20.49 | $22,539.00 |
DisclosureSEC source: 0001127602-24-025865 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,207 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on July 18, 2024. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 20:31 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2,011 | $21.03 | $42,281.48 |
DisclosureSEC source: 0001127602-24-025708 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,307 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.755 to $21.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 20:39 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 24 | $24.04 | $577.04 |
DisclosureSEC source: 0001127602-24-024288 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,971 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 21:49 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 61 | $24.09 | $1,469.28 |
DisclosureSEC source: 0001127602-24-024260 · form4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,995 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:49 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 36 | $24.77 | $891.54 |
DisclosureSEC source: 0001127602-24-024260 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 9,056 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 21:58 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 95 | $23.25 | $2,208.77 |
DisclosureSEC source: 0001127602-24-023869 · form4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 9,092 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.94 to $23.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 21:58 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 1,716 | $23.25 | $39,897.34 |
DisclosureSEC source: 0001127602-24-023869 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,318 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.94 to $23.17 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:56 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023716 · form4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 9,187 F2 · price: Represents RSUs that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's spouse's cash bonus earned for the fiscal first half of the year ending January 31, 2025 under the Issuer's Variable Compensation Plan. The Reporting Person's spouse elected to convert such portion of her earned cash bonus into RSUs representing 115% of such amount. The number of RSUs granted is based on a per share value of $23.55, the closing price of the Issuer's common stock on September 6, 2024. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:56 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 2,816 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023716 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,034 F1 · price: Represents Restricted Stock Units ("RSUs") that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's cash bonus earned for the first half of the fiscal year ending January 31, 2025 under the Issuer's Senior Executive Cash Incentive Bonus Plan. The Reporting Person elected to convert such portion of his cash bonus into RSUs representing 115% of the earned cash bonus amount. The number of RSUs granted is based on a per share value of $23.55, the closing price of the Issuer's common stock on September 6, 2024. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:05 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-022356 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 8,953 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 10% of the RSUs shall vest on August 15, 2025, 20% of the RSUs shall vest on August 15, 2026, 30% of the RSUs shall vest on August 15, 2027 and 40% of the RSUs shall vest on August 15, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 21:31 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 1,820 | $23.74 | $43,198.79 |
DisclosureSEC source: 0001127602-24-020618 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,218 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 20:29 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 27 | $20.24 | $546.39 |
DisclosureSEC source: 0001127602-24-019155 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 6,953 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:35 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 66 | $19.73 | $1,302.33 |
DisclosureSEC source: 0001127602-24-019127 · form4.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 6,980 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:35 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 41 | $19.20 | $787.08 |
DisclosureSEC source: 0001127602-24-019127 · form4.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,046 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 20:24 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 269 | $22.85 | $6,145.84 |
DisclosureSEC source: 0001562180-24-003481 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,087 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.56 to $23.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 20:13 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2,212 | $22.86 | $50,560.57 |
DisclosureSEC source: 0001562180-24-003446 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,038 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.63 to $23.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:18 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2 | $23.02 | $46.03 |
DisclosureSEC source: 0001562180-24-003385 · primarydocument.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,356 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:18 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 245 | $22.62 | $5,540.94 |
DisclosureSEC source: 0001562180-24-003385 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,358 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:18 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 39 | $23.02 | $897.64 |
DisclosureSEC source: 0001562180-24-003385 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,250 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:18 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 3,875 | $22.62 | $87,637.39 |
DisclosureSEC source: 0001562180-24-003385 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,289 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 23:37 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 508 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003373 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,603 F2 · shares: Represents RSUs that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's spouse's cash bonus earned for the fiscal year ended January 31, 2024 under the Issuer's Variable Compensation Plan. The Reporting Person's spouse elected to convert such portion of her earned cash bonus into RSUs representing 115% of such amount. The number of RSUs granted are based on a per share value of $21.79, the closing price of the Issuer's common stock on April 5, 2024. F2 · price: Represents RSUs that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's spouse's cash bonus earned for the fiscal year ended January 31, 2024 under the Issuer's Variable Compensation Plan. The Reporting Person's spouse elected to convert such portion of her earned cash bonus into RSUs representing 115% of such amount. The number of RSUs granted are based on a per share value of $21.79, the closing price of the Issuer's common stock on April 5, 2024. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 23:37 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 6,105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-003373 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,164 F1 · shares: Represents Restricted Stock Units ("RSUs") that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's cash bonus earned for the fiscal year ended January 31, 2024 under the Issuer's Senior Executive Cash Incentive Bonus Plan. The Reporting Person elected to convert 50% of such cash bonus into RSUs representing 115% of the earned cash bonus amount. The number of RSUs granted are based on a per share value of $21.79, the closing price of the Issuer's common stock on April 5, 2024. F1 · price: Represents Restricted Stock Units ("RSUs") that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's cash bonus earned for the fiscal year ended January 31, 2024 under the Issuer's Senior Executive Cash Incentive Bonus Plan. The Reporting Person elected to convert 50% of such cash bonus into RSUs representing 115% of the earned cash bonus amount. The number of RSUs granted are based on a per share value of $21.79, the closing price of the Issuer's common stock on April 5, 2024. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 20:11 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 30 | $23.66 | $709.79 |
DisclosureSEC source: 0001562180-24-002898 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,095 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.28 to $24.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 20:21 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 402 | $23.27 | $9,355.87 |
DisclosureSEC source: 0001562180-24-002874 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,125 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $2.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:21 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 46 | $22.22 | $1,021.95 |
DisclosureSEC source: 0001562180-24-002874 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,527 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.17 to $22.235 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 21:52 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 30,659 | $24.12 | $739,544.13 |
DisclosureSEC source: 0001562180-24-000531 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,059 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.70 to $24.47 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:52 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2,318 | $24.55 | $56,896.47 |
DisclosureSEC source: 0001562180-24-000531 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,718 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.665 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:31 UTC | Phreesia, Inc. PHR · Entity 2606 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000262 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,036 F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four substantially equal annual installments beginning on January 2, 2025. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:13 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 25 | $23.72 | $593.08 |
DisclosureSEC source: 0001562180-23-008506 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,573 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.595 to $23.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:13 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 234 | $23.15 | $5,417.73 |
DisclosureSEC source: 0001562180-23-008506 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 7,598 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.96 to $23.33 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 18, 2023 Filed May 9, 2025 20:24 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 100 | $23.15 | $2,315.27 |
DisclosureSEC source: 0001127602-25-013853 · form4.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 9,904 F4 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of RSUs. The transaction was originally reported in a Form 4 filed on December 20, 2023 that contained an error in the number of shares in Column 4. The transaction is being re-reported in order to correct the number of shares in Column 4. Forms 4 filed after the transaction date understated the total common stock holdings of the Reporting Person's spouse by 134 shares. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.96 to $23.33 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The total in Column 5 has been adjusted to correct (i) an overstatement of holdings by 116 shares first reflected in a Form 4 filed on September 14, 2022 and (ii) an overstatement of holdings by 236 shares first reflected in a Form 4 filed on April 12, 2023. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 22:11 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 2,078 | $16.61 | $34,513.50 |
DisclosureSEC source: 0001562180-23-007332 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,036 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the reporting person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.46 to $16.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:17 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 26 | $19.79 | $514.52 |
DisclosureSEC source: 0001562180-23-006967 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 7,832 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6848 to $19.91 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:17 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 38 | $19.71 | $748.98 |
DisclosureSEC source: 0001562180-23-006967 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 7,858 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:17 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 66 | $19.59 | $1,293.02 |
DisclosureSEC source: 0001562180-23-006967 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 7,896 F1 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.481 to $19.6771 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 21:04 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 5 | $21.20 | $106.02 |
DisclosureSEC source: 0001562180-23-006858 · primarydocument.xml · nonDerivative · entry 9 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 7,962 F3 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.17 to $21.24 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 21:04 UTC | Phreesia, Inc. PHR · Entity 2606 | SaleCommon Stock | 114 | $20.30 | $2,314.55 |
DisclosureSEC source: 0001562180-23-006858 · primarydocument.xml · nonDerivative · entry 8 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 7,967 F3 · kind: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the Reporting Person's tax withholding obligations in connection with the settlement of an award of RSUs. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.11 to $21.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.